Research programme: allergy therapeutics - Intrexon/Stallergenes Greer plc

Latest Information Update: 26 Apr 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator ActoGeniX
Developer Intrexon Corporation; Stallergenes Greer plc
Class
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hypersensitivity

Most Recent Events

20 Nov 2014 Stallergenes exercises option to pursue exclusive development of oral allergy therapeutics
20 Nov 2014 Preclinical trials in Hypersensitivity in Belgium (PO)
20 Nov 2014 Preclinical trials in Hypersensitivity in France (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.